Jonathan Schoenfeld Answers: Which Patients Benefit Most from Immunotherapy and Radiation

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.

Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

A retrospective cohort demonstrated that patients who are treated with antibiotics within 1 year before immune checkpoint inhibitor therapy may experience worse overall survival.

Lindsay Diamond, MSN, AGNP-C, AOCNP, unpacks the significance of recent advances in the bladder cancer space.